Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
Business Wire India− TAKHZYRO Approved for Adult and Pediatric Patients 12 Years of Age and Older1 − Approval Based on Results of Global Phase 3 HELP Study™, Phase 3 HELP…